Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age

NCT03658629 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT03658629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03658629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Lead sponsor
Novavax
Phase
Phase 2
Overall status
Terminated
Start date
September 24, 2018
Completion date
April 26, 2019
Enrollment
1,375 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human